Figure 1 from Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
Key Points
Best overall response showed significant increases in target lesion improvement in hormone receptor-positive breast cancer patients.
Among 33 evaluable patients, five achieved 100% target lesion responses, classified as partial responses due to other lesions.
Patients received no prior systemic therapy, indicating a need for effective treatment options in advanced stages.
Combination of gedatolisib, palbociclib, and letrozole may offer new therapeutic strategies, supporting further investigation.
Abstract
Best overall response and target lesion improvement. Percentage change from baseline in the sum of the diameters of all target lesions at the time of best response. There were five subjects with 100% target lesion responses, but they were classified as PR due to nontarget lesions. Each bar represents a single patient with no prior systemic therapy for advanced breast cancer in the response evaluable set (N = 33).
Figure 1 from Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer | Synapse
Also Consider
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
2Figure 2 from Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer2025